Don’t look now, but Medtronic has quite possibly just become the poster child of the opposition against the Medical Device Tax. During a call with analysts in February, the med-tech giant said that it expected to pay up to $175 million in costs because of the tax. When the news broke, Medical Device Daily, as well as other media outlets, picked up the story, and rightly so. Outside of regulatory issues with the FDA, the Medical Device Tax is the biggest concern that keeps device makers up at night. Right now device makers are struggling to find a way they...
Corindus Vascular Robotics (Natick, Massachusetts) reported it has met the primary endpoints for its PRECISE trial and results indicate the Corpath 200 System could be considered as a safer alternative to manual PCI.
CHICAGO A new IT solution could give cardiologists and clinicians a single point of access to patient data and eliminate the boutique solution that has been the standard of the industry for years now.
CHICAGO Data presented from Edwards Lifescience's (Irvine, California) PARTNER trial at the American College of Cardiology's (ACC; Washington) 61st Annual Scientific Session and Expo on Monday, bolsters a less-invasive procedure using the firm's Sapien transcatheter heart valve and shows that the device has strong performance at two years.
CHICAGO — Data from two trials at the American College of Cardiology (ACC; Washington) 61st Annual Scientific Session and Expo, 2012 suggests that Medtronic's (Minneapolis) renal denervation system provides a significant benefit to patients suffering from treatment-resistant hypertension.
